Previous 10 | Next 10 |
2023-03-09 12:48:42 ET Gainers: Intuitive Machines ( LUNR ) +74% . Ocean Biomedical ( OCEA ) +72% . Holley ( HLLY ) +55% . Build-A-Bear Workshop ( BBW ) +23% . Avenue Therapeutics ( ATXI ) +21% . Digital Brands Group ( DBGI...
2023-03-09 11:33:06 ET Akebia Therapeutics ( NASDAQ: AKBA ) stock fell ~22% on Thursday despite Q4 results beating estimates. Net loss narrowed to -$7.55M, compared to -$70.68M in Q4 2021. Total revenue declined -7.4% Y/Y to $55.18. However, both numbers surpassed a...
2023-03-09 10:57:18 ET Although Akebia Therapeutics' ( NASDAQ: AKBA ) Q4 2022 results beat on the top and bottom lines, the company's 2023 product revenue guidance failed to impress investors, sending shares down 24% . Akebia sees net product revenue guidance at $175M-...
2023-03-09 10:01:05 ET Gainers: Ocean Biomedical OCEA +57% . Avenue Therapeutics ( ATXI ) +21% . Unicycive Therapeutics ( UNCY ) +19% . Assertio ( ASRT ) +12% . Immuneering ( IMRX ) +11% . Losers: InVivo Therapeutics NVIV ...
2023-03-09 08:45:20 ET Silvergate Capital SI -36% on plans to wind down operations, liquidate Silvergate Bank . SVB Financial SIVB -28% on $1.25B stock offering, $500M depositary share offering . Arhaus ARHS -11% on Q4 earnings release . Altamira Th...
2023-03-09 07:42:09 ET Akebia press release ( NASDAQ: AKBA ): Q4 GAAP EPS of -$0.04 beats by $0.15 . Revenue of $55.18M (-7.4% Y/Y) beats by $7.78M . Net product revenue was $49.7 million in the fourth quarter of 2022 compared to $42.1 million in the fourth qua...
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Business Highlights PR Newswire Akebia to host conference call on March 9 at 8:30 a.m. ET Receives positive CHMP opinion for Vafseo™ (vadadustat); anticipates ...
Insider trading activity in stocks, including penny stocks , involves company insiders buying or selling company stock. Insiders can be executives, directors, and major shareholders of a company. They report these trades to the Securities and Exchange Commission (SEC) using forms such as Form...
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results and Discuss Recent Business Highlights PR Newswire Akebia to Host Conference Call CAMBRIDGE, Mass. , March 2, 2023 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), ...
Akebia Therapeutics ( NASDAQ: AKBA ) added ~11% pre-market Friday after announcing that an independent group of medical experts has recommended the approval of its lead asset, vadadustat, as a treatment for anemia linked to chronic kidney disease in adults on dialysis. With the so...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets PR Newswire Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement wit...
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference PR Newswire CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purp...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer PR Newswire CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with t...